Immunotherapy for Ovarian Cancer: What's Next?
- 1 March 2011
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (7) , 925-933
- https://doi.org/10.1200/jco.2009.27.2369
Abstract
In the past decade, we have witnessed important gains in the treatment of ovarian cancer; however, additional advances are required to reduce mortality. With compelling evidence that ovarian cancer...Keywords
This publication has 121 references indexed in Scilit:
- Engineering lymphocyte subsets: tools, trials and tribulationsNature Reviews Immunology, 2009
- Intraepithelial T cells and tumor proliferationCancer, 2009
- Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the MorningImmunity, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 lossLaboratory Investigation, 2009
- Use of tumour-responsive T cells as cancer treatmentThe Lancet, 2009
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences, 2008
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Checkpoint Blockade in Cancer ImmunotherapyPublished by Elsevier ,2006